Literature DB >> 28807942

Nuclear FAK and Runx1 Cooperate to Regulate IGFBP3, Cell-Cycle Progression, and Tumor Growth.

Marta Canel1,2, Adam Byron1, Andrew H Sims1, Jessy Cartier3, Hitesh Patel1, Margaret C Frame1, Valerie G Brunton1, Bryan Serrels4, Alan Serrels4,2.   

Abstract

Nuclear focal adhesion kinase (FAK) is a potentially important regulator of gene expression in cancer, impacting both cellular function and the composition of the surrounding tumor microenvironment. Here, we report in a murine model of skin squamous cell carcinoma (SCC) that nuclear FAK regulates Runx1-dependent transcription of insulin-like growth factor binding protein 3 (IGFBP3), and that this regulates SCC cell-cycle progression and tumor growth in vivo Furthermore, we identified a novel molecular complex between FAK and Runx1 in the nucleus of SCC cells and showed that FAK interacted with a number of Runx1-regulatory proteins, including Sin3a and other epigenetic modifiers known to alter Runx1 transcriptional function through posttranslational modification. These findings provide important new insights into the role of FAK as a scaffolding protein in molecular complexes that regulate gene transcription. Cancer Res; 77(19); 5301-12. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28807942      PMCID: PMC6126615          DOI: 10.1158/0008-5472.CAN-17-0418

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

Review 1.  Sin3: insight into its transcription regulatory functions.

Authors:  Rama Kadamb; Shilpi Mittal; Nidhi Bansal; Harish Batra; Daman Saluja
Journal:  Eur J Cell Biol       Date:  2013-10-09       Impact factor: 4.492

Review 2.  Posttranslational modifications of RUNX1 as potential anticancer targets.

Authors:  S Goyama; G Huang; M Kurokawa; J C Mulloy
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

Review 3.  FAK signaling in human cancer as a target for therapeutics.

Authors:  Brian Y Lee; Paul Timpson; Lisa G Horvath; Roger J Daly
Journal:  Pharmacol Ther       Date:  2014-10-12       Impact factor: 12.310

Review 4.  Focal adhesion kinase: a potential target in cancer therapy.

Authors:  Maroesja J van Nimwegen; Bob van de Water
Journal:  Biochem Pharmacol       Date:  2006-09-25       Impact factor: 5.858

Review 5.  AML1/Runx1 as a versatile regulator of hematopoiesis: regulation of its function and a role in adult hematopoiesis.

Authors:  Mineo Kurokawa
Journal:  Int J Hematol       Date:  2006-08       Impact factor: 2.490

6.  Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling.

Authors:  Yuliya Pylayeva; Kelly M Gillen; William Gerald; Hilary E Beggs; Louis F Reichardt; Filippo G Giancotti
Journal:  J Clin Invest       Date:  2009-01-19       Impact factor: 14.808

7.  Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer.

Authors:  Paolo P Provenzano; David R Inman; Kevin W Eliceiri; Hilary E Beggs; Patricia J Keely
Journal:  Am J Pathol       Date:  2008-10-09       Impact factor: 4.307

8.  AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.

Authors:  T Okuda; J van Deursen; S W Hiebert; G Grosveld; J R Downing
Journal:  Cell       Date:  1996-01-26       Impact factor: 41.582

9.  Visualizing spatiotemporal dynamics of multicellular cell-cycle progression.

Authors:  Asako Sakaue-Sawano; Hiroshi Kurokawa; Toshifumi Morimura; Aki Hanyu; Hiroshi Hama; Hatsuki Osawa; Saori Kashiwagi; Kiyoko Fukami; Takaki Miyata; Hiroyuki Miyoshi; Takeshi Imamura; Masaharu Ogawa; Hisao Masai; Atsushi Miyawaki
Journal:  Cell       Date:  2008-02-08       Impact factor: 41.582

10.  Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.

Authors:  Hong Jiang; Samarth Hegde; Brett L Knolhoff; Yu Zhu; John M Herndon; Melissa A Meyer; Timothy M Nywening; William G Hawkins; Irina M Shapiro; David T Weaver; Jonathan A Pachter; Andrea Wang-Gillam; David G DeNardo
Journal:  Nat Med       Date:  2016-07-04       Impact factor: 53.440

View more
  19 in total

1.  The autophagy protein Ambra1 regulates gene expression by supporting novel transcriptional complexes.

Authors:  Christina Schoenherr; Adam Byron; Billie Griffith; Alexander Loftus; Jimi C Wills; Alison F Munro; Alex von Kriegsheim; Margaret C Frame
Journal:  J Biol Chem       Date:  2020-07-02       Impact factor: 5.157

2.  IL-33 and ST2 mediate FAK-dependent antitumor immune evasion through transcriptional networks.

Authors:  Bryan Serrels; Niamh McGivern; Marta Canel; Adam Byron; Sarah C Johnson; Henry J McSorley; Niall Quinn; David Taggart; Alex Von Kreigsheim; Stephen M Anderton; Alan Serrels; Margaret C Frame
Journal:  Sci Signal       Date:  2017-12-05       Impact factor: 8.192

Review 3.  Targeting FAK in anticancer combination therapies.

Authors:  John C Dawson; Alan Serrels; Dwayne G Stupack; David D Schlaepfer; Margaret C Frame
Journal:  Nat Rev Cancer       Date:  2021-03-17       Impact factor: 60.716

4.  Nuclear Focal Adhesion Kinase Controls Vascular Smooth Muscle Cell Proliferation and Neointimal Hyperplasia Through GATA4-Mediated Cyclin D1 Transcription.

Authors:  Kyuho Jeong; Jung-Hyun Kim; James M Murphy; Hyeonsoo Park; Su-Jeong Kim; Yelitza A R Rodriguez; Hyunkyung Kong; Chungsik Choi; Jun-Lin Guan; Joan M Taylor; Thomas M Lincoln; William T Gerthoffer; Jun-Sub Kim; Eun-Young Erin Ahn; David D Schlaepfer; Ssang-Taek Steve Lim
Journal:  Circ Res       Date:  2019-05-17       Impact factor: 17.367

5.  A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability.

Authors:  Emily R Webb; Xue-Feng Li; John C Dawson; Carolin Temps; Daniel Lietha; Morwenna Muir; Kenneth G Macleod; Teresa Valero; Alison F Munro; Rafael Contreras-Montoya; Juan R Luque-Ortega; Craig Fraser; Henry Beetham; Christina Schoenherr; Maria Lopalco; Mark J Arends; Margaret C Frame; Bin-Zhi Qian; Valerie G Brunton; Neil O Carragher; Asier Unciti-Broceta
Journal:  Cancer Res       Date:  2021-08-20       Impact factor: 13.312

6.  Profiling the epigenetic interplay of lncRNA RUNXOR and oncogenic RUNX1 in breast cancer cells by gene in situ cis-activation.

Authors:  Yuanyuan Nie; Lei Zhou; Hong Wang; Naifei Chen; Lin Jia; Cong Wang; Yichen Wang; Jingcheng Chen; Xue Wen; Chao Niu; Hui Li; Rui Guo; Songling Zhang; Jiuwei Cui; Andrew R Hoffman; Ji-Fan Hu; Wei Li
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

7.  [Nucleus translocation of membrane/cytoplasm proteins in tumor cells].

Authors:  Ziling Zhu; Jing Tan; Hong Deng
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2019-05-25

8.  FAK in the nucleus prevents VSMC proliferation by promoting p27 and p21 expression via Skp2 degradation.

Authors:  Kyuho Jeong; James M Murphy; Eun-Young Erin Ahn; Ssang-Taek Steve Lim
Journal:  Cardiovasc Res       Date:  2022-03-16       Impact factor: 13.081

Review 9.  Every step of the way: integrins in cancer progression and metastasis.

Authors:  Hellyeh Hamidi; Johanna Ivaska
Journal:  Nat Rev Cancer       Date:  2018-09       Impact factor: 60.716

10.  FAM64A is an androgen receptor-regulated feedback tumor promoter in prostate cancer.

Authors:  Yingchen Zhou; Longhua Ou; Jinming Xu; Haichao Yuan; Junhua Luo; Bentao Shi; Xianxin Li; Shangqi Yang; Yan Wang
Journal:  Cell Death Dis       Date:  2021-07-02       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.